Galapagos (GLPG)
(Delayed Data from NSDQ)
$29.58 USD
+0.24 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.58 USD
+0.24 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.
Gilead & Galapagos Announce Positive Data on UC Candidate
by Zacks Equity Research
Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.
Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.
Galapagos Begins Dosing With GLPG3970 in Psoriasis Study
by Zacks Equity Research
Galapagos (GLPG) doses the first patient in an early-stage study on its Toledo compound GLPG3970 for treating psoriasis. The same is also being studied for ulcerative colitis and rheumatoid arthritis.
Gilead & Galapagos' RA Drug Receives Approval in Europe
by Zacks Equity Research
Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.
Galapagos Gets First Commercial Drug With Jyseleca Approval
by Zacks Equity Research
Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.
Gilead's Rheumatoid Arthritis Drug Gets Approval in Japan
by Zacks Equity Research
Gilead's (GILD) rheumatoid arthritis drug, Jyseleca, wins approval in Japan.
New Strong Sell Stocks for September 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Galapagos (GLPG) Surges: Stock Moves 8.8% Higher
by Zacks Equity Research
Galapagos (GLPG) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Company News for Aug 20, 2020
by Zacks Equity Research
Companies In The News Are: MNTA, JNJ, TGT, REGN, GLPG, GILD.
Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug
by Zacks Equity Research
Gilead (GILD) suffers a setback as the FDA issues a CRL for its rheumatoid arthritis drug.
Gilead (GILD) Misses on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Gilead (GILD) reports weaker-than-expected results for the second quarter but ups annual guidance.
Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Gilead's Rating Upgraded on Potential Coronavirus Drug Sales
by Zacks Equity Research
Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.
Gilead (GILD) Gains 13% YTD on Coronavirus Drug Development
by Zacks Equity Research
Gilead's experimental coronavirus drug, remdesivir, shows promise. The stock has been in news since the onset of the year on updates from the same.
Gilead, Galapagos Announce Positive Data on Inflammatory Drug
by Zacks Equity Research
Gilead (GILD) and Galapagos announce positive data on filgotinib for the treatment of ulcerative colitis.
Why Galapagos (GLPG) Might Surprise This Earnings Season
by Zacks Equity Research
Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Gilead (GILD) Partners With Eisai for RA Candidate in Japan
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
by Zacks Equity Research
Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat
by Zacks Equity Research
Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.